SAMe 400

SAMe 400

Jarrow Formulas4.5 (3,016 ratings)
Format:Tablet Quantity: 60 Tablet(s) · 60 servings
Goals
$55.99 $0.93 per serving
Pure FormulasLowest$55.99Amazon$56.94Daily Vita$59.99Vitacost$67.99Vitacost$69.09iHerb$69.75iHerb$69.75

About this product

The tablet offers a full SAMe amount in one unit and a longer supply. It covers several common SAMe goals through a single active.

No stable salt or acid-resistant delivery feature is stated. Packaging and active-ion yield also remain unclear.

The larger bottle is convenient for established users, but quality documentation is weak. Better-protected options are easier to justify.

Who is it for
  • Established full-dose SAMe users
  • Adults wanting a larger tablet supply
  • People accepting limited form detail
Best for
  • Longer full-strength routines
  • Single-tablet dosing
  • Mood and joint support

Pros

  • Full amount per tablet
  • Larger supply
  • Simple formula
  • Exact serving weight

Cons

  • Salt form is unspecified
  • No enteric coating
  • No moisture protection disclosed
  • Only average value

Warnings

  • SAMe may provoke mania in bipolar disorder
  • Combining with serotonergic medicines may create serotonin-syndrome risk
  • Possible effects include insomnia, anxiety, and digestive upset

Product analysis

75 out of 100
A convenient longer supply of full-dose SAMe with insufficient stability and delivery detail.

AI assessment of the formula, label and price. How scoring works

Nutrient quality84

Neither a stabilized salt nor acid-resistant delivery is identified. A full commonly used amount provides strong active depth, although net SAMe yield remains unclear.

Ingredient transparency79

The active amount is disclosed without a hidden blend. Missing net active yield, complete directions, and non-active ingredients leave important gaps.

Customer satisfaction69

The supplied average rating is strong and the rating volume is substantial. No specific experience details were provided to judge repeated complaints or purpose alignment.

Value for money65

Delivery limitations or high cost weaken practical value. Better-protected or more efficiently priced alternatives are more competitive.

Format
Tablet
Container
60 Tablet(s)
Per serving
$0.93
Also available
SAMe 200SAMe 200 mg • 60 Tablet(s) • 60 servings$15.00
Customer rating
4.5 · 3,016 ratings
Report analysis

Goals

Joint Health
Joint Health
Impact
High effect
B- Ingredient FitF PathwaysB+ EvidenceA+ Formulation Logic
SAMe · 400 mg

SAMe may ease symptoms of osteoarthritis, but the benefit is uncertain. Any improvement concerns how a joint feels and functions, rather than repair of damaged cartilage or prevention of future problems. The active ingredient is identified here, although the salt name alone doesn't verify the coating, stability or absorption needed to know how closely this preparation matches others.

How this product is rated for Joint Health

Ingredient fit75

SAMe may ease osteoarthritis symptoms, but the benefit is uncertain.
Goal fit
SAMe may ease osteoarthritis symptoms, but the benefit is uncertain.
Dose adequacy
The serving provides 400 mg active SAMe, below the 800 mg comparison anchor; salt mass is not extra active SAMe.

Pathways15

SAMe relates mainly to the cartilage matrix, the material that gives cartilage its structure; symptom relief does not mean cartilage repair.
Depth
SAMe relates mainly to the cartilage matrix, the material that gives cartilage its structure; symptom relief does not mean cartilage repair.
Breadth
The main connection concerns cartilage structure, with a smaller connection to inflammation; this does not imply broad joint protection.

Evidence81

SAMe may ease osteoarthritis symptoms, but the benefit is uncertain. The active SAMe amount does not verify its coating, stability or absorption.
Evidence strength
SAMe may ease osteoarthritis symptoms, but the benefit is uncertain.
Studied preparation
The active SAMe amount does not verify its coating, stability or absorption.

Formulation logic100

SAMe has no missing required partner here, and no particular ingredient conflict is identified.
Partner coverage
SAMe does not require another ingredient for its individual role here.
Conflicts
No particular ingredient conflict is identified.
Effective doses
The serving provides 400 mg active SAMe, below the 800 mg comparison anchor; salt mass is not extra active SAMe.
Study evidence
SAMe Supportive 9 studies
Detoxification
Detoxification
Impact
Highest effect
A Ingredient FitC- PathwaysA- EvidenceA+ Formulation Logic
SAMe · 400 mg

Whether SAMe helps your body clear everyday toxins is unclear. It relates to the supply of methyl groups, which are small chemical units used in normal body processes. That role does not show that taking SAMe improves routine toxin removal, and its use for particular liver conditions cannot be assumed to provide the same benefit for everyday cleansing.

How this product is rated for Detoxification

Ingredient fit95

SAMe relates to methyl-group supply; routine toxin clearance remains uncertain.
Goal fit
SAMe is the sole active ingredient relevant here.
Dose adequacy
The serving supplies 400 mg SAMe, matching the upper comparison anchor.

Pathways59

SAMe relates to methyl-group supply.
Depth
SAMe relates to methyl-group supply.
Breadth
The connection is concentrated in methyl-group supply.

Evidence86

Routine toxin removal from SAMe remains unclear.
Evidence strength
Routine toxin removal from SAMe remains unclear.
Studied preparation
The declared SAMe amount does not confirm a routine cleansing effect.

Formulation logic100

The individual ingredient roles do not require an added partner. No particular ingredient conflict is identified.
Partner coverage
No additional partner ingredient is required for the individual roles described here.
Conflicts
No particular ingredient conflict is identified.
Effective doses
The serving supplies 400 mg SAMe, matching the upper comparison anchor.
Study evidence
SAMe Supportive 30 studies
Mood Support
Mood Support
Impact
Moderate effect
B- Ingredient FitF PathwaysC+ EvidenceA+ Formulation Logic
SAMe · 400 mg

SAMe may help with depressive symptoms in some treatment settings, but whether it improves everyday mood in generally healthy adults is unclear. Its connection to mood comes from contexts involving diagnosed depression and, sometimes, concurrent treatment. That makes it difficult to predict a benefit from taking this serving on its own.

How this product is rated for Mood Support

Ingredient fit75

SAMe is the relevant ingredient for mood, with no additional unrelated actives identified. Amounts differ in how closely they match the ingredient comparisons.
Goal fit
The relevant ingredients connect directly or conditionally to mood, without additional unrelated actives.
Dose adequacy
SAMe: 400 mg per serving. These are ingredient comparisons, not guarantees of a mood benefit.

Pathways11

The ingredients relate mainly to mood-related nerve signalling; that role alone does not predict a benefit.
Depth
The ingredients relate mainly to mood-related nerve signalling; that role alone does not predict a benefit.
Breadth
The relevant ingredient has a narrow mood-related role rather than several distinct supported benefits.

Evidence67

SAMe has possible benefits in depression-treatment contexts; everyday mood benefits in healthy adults remain unclear.
Evidence strength
SAMe has possible benefits in depression-treatment contexts; everyday mood benefits in healthy adults remain unclear.
Studied preparation
The declared ingredient identities are usable for comparison, but matching an ingredient does not guarantee the same mood effect.

Formulation logic100

The relevant ingredients have no missing required partner or identified internal conflict. This does not imply an added benefit from combining them.
Partner coverage
No required partner ingredient is missing for the relevant ingredients.
Conflicts
No particular conflict among these ingredients is identified.
Effective doses
The declared amount is within the included comparison range; this is not a minimum effective dose or a prediction of benefit.
Study evidence
SAMe Disputed 20 studies
Stress Relief
Stress Relief
Impact
High effect
B- Ingredient FitF PathwaysC+ EvidenceA+ Formulation Logic
SAMe · 400 mg

SAMe's connection to stress is indirect, through its mood and metabolic roles. Whether taking it helps you feel less stressed in everyday life is unclear. The 400 mg serving provides a known amount, but that detail doesn't resolve the uncertainty about stress relief.

How this product is rated for Stress Relief

Ingredient fit75

SAMe provide the relevant connection to stress relief. That connection remains indirect and uncertain.
Goal fit
SAMe relate to this goal.
Dose adequacy
SAMe supplies 400 mg, matching its lower comparison quantity and half its 800 mg middle reference; this does not confirm stress relief.

Pathways17

The ingredients relate mainly to mood-related processes; this does not guarantee that you will feel less stressed.
Depth
Mood-related processes are the main connection here.
Breadth
The connection is narrow and indirect, rather than spanning several distinct stress-related functions.

Evidence65

SAMe has an indirect and unconfirmed connection to stress relief.
Evidence strength
SAMe’s mood and metabolic roles do not confirm a practical everyday stress benefit.
Studied preparation
The declared SAMe preparation matches the preparation reference, while stress benefit remains unconfirmed.

Formulation logic100

No particular ingredient conflict or missing required partner is identified for the relevant ingredients.
Partner coverage
The relevant ingredients can act alone or have their specified partner.
Conflicts
No particular ingredient conflict is identified.
Effective doses
SAMe supplies 400 mg, matching its lower comparison quantity and half its 800 mg middle reference; this does not confirm stress relief.
Study evidence
SAMe Not classified

No linked studies yet.

Ingredients

IngredientAmount per servingScore
S-Adenosyl Methionine
400 mg 96
Gluten Free Adults 18–50 Vegan Women Vegetarian
Report overview
SAMe · 400 mg OverallScore96
A+ Active Ingredient Quality & BioavailabilityA+ Dose, Safety & Label TransparencyB+ Value
It lists 400 mg of SAMe per serving and names the SAMe tosylate disulfate form. The label says the tablets are blister-packed and clearly identifies active SAMe; its cost per equivalent 400 mg amount is moderate.
How this ingredient is rated

Active Ingredient Quality & Bioavailability100

The label names SAMe tosylate disulfate and reports blister packaging, which helps limit moisture exposure.
Stabilized Salt Form
The label names SAMe tosylate disulfate, but doesn't clarify how much of the preparation uses that form.
Packaging Integrity
The label says the tablets are blister-packed, which helps protect them from moisture exposure.

Dose, Safety & Label Transparency100

The label clearly identifies the active SAMe amount and lists 400 mg per serving.
Active Dosage Strength
The serving lists 400 mg of SAMe.
Net SAMe Yield Transparency
The label clearly identifies the active SAMe amount.

Value80

The cost for an equivalent 400 mg amount is moderate.
Price Per 400mg Active Dose
The cost per equivalent 400 mg amount is moderate.
View ingredientView products
Loading alternative details
85 Performance

SAMe 400 mg

Lake Avenue Nutrition

A stabilized salt and enteric coating protect a full SAMe amount during storage and passage through the stomach. Its balance of dose, stabilization, or gastric protection is stronger than less protected eligible formulas. Net active yield and moisture-resistant packaging remain unclear.

84 Performance

SAMe 400 mg

Life Extension

Enteric coating protects a full SAMe amount from stomach acid and supports purposeful delivery. Its balance of dose, stabilization, or gastric protection is stronger than less protected eligible formulas. The stabilized salt, net active yield, and moisture protection are not identified.

84 Performance

SAMe 400 mg

NOW

A stabilized disulfate tosylate salt supplies a full SAMe amount in one tablet. Its balance of dose, stabilization, or gastric protection is stronger than less protected eligible formulas. Enteric and sealed moisture protection are not stated, and net active yield remains unclear.

74 Budget

SAMe 200

Jarrow Formulas

A common starting SAMe amount provides a simple, low-cost option. It lowers routine cost versus the original. Neither a stabilized salt nor acid-resistant delivery is identified, so protected active yield is uncertain.

83 Budget

SAMe 200 mg

NOW

A stabilized disulfate tosylate salt provides a credible common starting amount at efficient routine value. It lowers routine cost versus the original. Enteric protection, net active yield, and moisture-resistant packaging are not stated.

84 Budget

SAMe 400 mg

Nutricost

A stabilized salt provides a full SAMe amount with efficient dose value. It lowers routine cost versus the original. The two-capsule serving has no stated acid resistance, and moisture protection is unclear.

84 Value

SAMe 400 mg

NOW

A stabilized disulfate tosylate salt provides a full SAMe amount with favorable dose value. Compared with the original, its delivery design and routine economics offer a useful value trade-off. Enteric protection and sealed moisture protection are not stated.

80 Value

SAMe 400 mg

Swanson

A stable disulfate tosylate form provides a full SAMe amount in one tablet. Compared with the original, its delivery design and routine economics offer a useful value trade-off. Enteric protection, net active yield, and moisture-resistant packaging are not stated.

78 Value

SAMe 200 mg S-Adenosyl-Methionine

Life Extension

Enteric coating protects a common starting SAMe amount from stomach acid. Compared with the original, its delivery design and routine economics offer a useful value trade-off. The salt form, net active yield, and moisture protection are not identified.

Report alternatives

Sources

Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.

  1. Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: A systematic review.
    Noureddin M; Sander-Struckmeier S; Mato JM · World journal of hepatology · 2020
    Systematic review9 studies pooledDetoxification forSAMe
  2. Ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial.
    Zhang L; Liu XH; Qi HB; Li Z; Fu XD; Chen L; Shao Y · European review for medical and pharmacological sciences · 2016
    Randomized trial120 participantsDetoxification forSAMe
  3. S-adenosyl-L-methionine for the treatment of chronic liver disease: a systematic review and meta-analysis.
    Guo T; Chang L; Xiao Y; Liu Q · PloS one · 2015
    Meta-analysis705 participants11 studies pooledDetoxification forSAMe
  4. Protective effect of S-adenosylmethionine on hepatic ischemia-reperfusion injury during hepatectomy in HCC patients with chronic HBV infection.
    Liu GY; Wang W; Jia WD; Xu GL; Ma JL; Ge YS; Yu JH; Sun QK; Meng FL · World journal of surgical oncology · 2014
    Non-randomized trial81 participantsDetoxification forSAMe
  5. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial.
    Mato JM; Cámara J; Fernández de Paz J; Caballería L; Coll S; Caballero A; García-Buey L; Beltrán J; Benita V; Caballería J; Solà R; Moreno-Otero R; Barrao F; Martín-Duce A; Correa JA; Parés A; Barrao E; García-Magaz I; Puerta JL; Moreno J; Boissard G; Ortiz P; Rodés J · Journal of hepatology · 1999
    Randomized trial123 participantsDetoxification forSAMe
  6. S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. [ISRCTN36233495].
    Najm WI; Reinsch S; Hoehler F; Tobis JS; Harvey PW · BMC musculoskeletal disorders · 2004
    Randomized trial61 participantsJoint Health forSAMe
  7. Italian double-blind multicenter study comparing S-adenosylmethionine, naproxen, and placebo in the treatment of degenerative joint disease.
    Caruso I; Pietrogrande V · The American journal of medicine · 1988
    Clinical trial734 participantsJoint Health forSAMe
  8. Double-blind multicentre study of the activity of S-adenosylmethionine in hip and knee osteoarthritis.
    Glorioso S; Todesco S; Mazzi A; Marcolongo R; Giordano M; Colombo B; Cherie-Ligniere G; Mattara L; Leardini G; Passeri M · International journal of clinical pharmacology research · 1985
    Randomized trial150 participantsJoint Health forSAMe
  9. A long-term (two years) clinical trial with S-adenosylmethionine for the treatment of osteoarthritis.
    König B · The American journal of medicine · 1988
    Single-arm trial108 participantsJoint Health forSAMe
  10. Exploring the mechanisms behind S-adenosylmethionine (SAMe) in the treatment of osteoarthritis.
    Hosea Blewett HJ · Critical reviews in food science and nutrition · 2008
    Narrative reviewJoint Health forSAMe
  11. Efficacy and tolerability of oral and intramuscular S-adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies.
    Delle Chiaie R; Pancheri P; Scapicchio P · The American journal of clinical nutrition · 2002
    Randomized trial576 participantsMood Support forSAMe
  12. A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder.
    Pancheri P; Scapicchio P; Chiaie RD · The international journal of neuropsychopharmacology · 2004
    Randomized trial293 participantsMood Support forSAMe
  13. Preliminary results of a randomized controlled trial carried out with a fixed combination of S-adenosyl-L-methionine and betaine versus amitriptyline in patients with mild depression.
    Di Pierro F; Settembre R · International journal of general medicine · 2015
    Randomized trial64 participantsMood Support forSAMe
  14. S-adenosylmethionine blood levels in major depression: changes with drug treatment.
    Bell KM; Potkin SG; Carreon D; Plon L · Acta neurologica Scandinavica. Supplementum · 1994
    Randomized trial26 participantsMood Support forSAMe
  15. Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses.
    Sarris J; Murphy J; Mischoulon D; Papakostas GI; Fava M; Berk M; Ng CH · The American journal of psychiatry · 2017
    Meta-analysisMood Support forSAMe